In HER2‐positive breast cancers, one of the most aggressive subtypes of breast cancer, KCTD10 induces RhoB degradation and activation of Rac1 [25], which promotes progression of tumors, and resistance to therapy [26]. Here, RAC1 is linked to breast carcinoma.